Drugplain

PAVBLU 2 mg/.05mL

aflibercept-ayyh · INJECTION, SOLUTION · Amgen, Inc

No Recall History
Plain English

PAVBLU is a injection, solution containing aflibercept-ayyh at 2 mg/.05mL, taken intravitreal. Manufactured by Amgen, Inc.

Key Facts

Brand Name
PAVBLU
Generic Name
aflibercept-ayyh
NDC Code (Product)
55513-056
Manufacturer
Amgen, Inc
Strength
2 mg/.05mL
Dosage Form
INJECTION, SOLUTION
Route
INTRAVITREAL
Marketing Status
Application #
BLA761298
Drug Class
Vascular Endothelial Growth Factor Inhibitor [EPC]
Marketing Start
10/28/2024

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

cough6 reports
endophthalmitis5 reports
eye pain5 reports
device physical property issue4 reports
headache4 reports
refusal of treatment by patient4 reports
intercepted product administration error3 reports
needle issue3 reports
off label use3 reports
treatment failure3 reports

Frequently Asked Questions

What is PAVBLU used for?

PAVBLU contains aflibercept-ayyh. It is a injection, solution taken intravitreal. Consult your doctor for specific uses.

Is PAVBLU a controlled substance?

PAVBLU is not classified as a controlled substance by the DEA.

What is the generic name for PAVBLU?

The generic name for PAVBLU is aflibercept-ayyh. There are no other listed brand versions of aflibercept-ayyh.

What is the NDC code for PAVBLU 2 mg/.05mL?

The NDC (National Drug Code) for PAVBLU 2 mg/.05mL is 55513-056, listed by Amgen, Inc.

Product NDC

55513-056

Package NDC

55513-056-01

Other PAVBLU Dosages

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)